NasdaqGS - Delayed Quote • USD
Halozyme Therapeutics, Inc. (HALO)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 5 |
Avg. Estimate | 0.69 | 0.72 | 3.68 | 4.56 |
Low Estimate | 0.63 | 0.69 | 3.58 | 4.41 |
High Estimate | 0.83 | 0.8 | 3.77 | 4.67 |
Year Ago EPS | 0.47 | 0.74 | 2.77 | 3.68 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 9 | 9 | 9 | 8 |
Avg. Estimate | 199.78M | 207.53M | 951.47M | 1.08B |
Low Estimate | 180.71M | 196M | 943.15M | 1.07B |
High Estimate | 220M | 223M | 966.56M | 1.1B |
Year Ago Sales | 175.51M | 199.95M | 829.25M | 951.47M |
Sales Growth (year/est) | 13.80% | 3.80% | 14.70% | 14.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.48 | 0.63 | 0.71 | 0.82 |
EPS Actual | 0.47 | 0.74 | 0.75 | 0.82 |
Difference | -0.01 | 0.11 | 0.04 | 0 |
Surprise % | -2.10% | 17.50% | 5.60% | 0.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.69 | 0.72 | 3.68 | 4.56 |
7 Days Ago | 0.7 | 0.73 | 3.69 | 4.56 |
30 Days Ago | 0.76 | 0.79 | 3.68 | 4.58 |
60 Days Ago | 0.77 | 0.81 | 3.55 | 4.43 |
90 Days Ago | 0.87 | 0.86 | 3.51 | 4.34 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | 1 | 1 | -- |
Up Last 30 Days | -- | 1 | 2 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
CURRENCY IN USD | HALO | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 46.80% | -- | -- | 2.60% |
Next Qtr. | -2.70% | -- | -- | 13.40% |
Current Year | 32.90% | -- | -- | 5.20% |
Next Year | 23.90% | -- | -- | 13.30% |
Next 5 Years (per annum) | 25.00% | -- | -- | 11.11% |
Past 5 Years (per annum) | 84.82% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/17/2024 |
Reiterates | Benchmark: Buy to Buy | 4/16/2024 |
Initiated | TD Cowen: Outperform | 2/29/2024 |
Reiterates | JMP Securities: Market Outperform to Market Outperform | 2/21/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
Reiterates | Benchmark: Buy to Buy | 1/19/2024 |
Related Tickers
GMAB Genmab A/S
27.46
-3.55%
IONS Ionis Pharmaceuticals, Inc.
41.84
-1.44%
BPMC Blueprint Medicines Corporation
90.73
-1.66%
INCY Incyte Corporation
51.18
-1.08%
UTHR United Therapeutics Corporation
235.95
-0.44%
FOLD Amicus Therapeutics, Inc.
10.17
-3.51%
EXEL Exelixis, Inc.
23.53
-0.76%
LEGN Legend Biotech Corporation
44.42
-1.66%
RPRX Royalty Pharma plc
28.11
+0.46%
RARE Ultragenyx Pharmaceutical Inc.
43.85
-0.97%